Cargando…

Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis

Chronic prostatitis (CP) is a common inflammatory condition of the prostate that is estimated to effect 2%–10% of the world’s male population. It can manifest as perineal, suprapubic, or lower back pain and urinary symptoms occurring with either recurrent bacterial infection [chronic bacterial prost...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Roy H., Zhang, Hongming, Kajsik, Michal, Płoski, Rafał, Rydzanicz, Malgorzata, Sabaka, Peter, Šutovský, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462781/
https://www.ncbi.nlm.nih.gov/pubmed/37649979
http://dx.doi.org/10.3389/fmed.2023.1238147
_version_ 1785098109074800640
author Stevens, Roy H.
Zhang, Hongming
Kajsik, Michal
Płoski, Rafał
Rydzanicz, Malgorzata
Sabaka, Peter
Šutovský, Stanislav
author_facet Stevens, Roy H.
Zhang, Hongming
Kajsik, Michal
Płoski, Rafał
Rydzanicz, Malgorzata
Sabaka, Peter
Šutovský, Stanislav
author_sort Stevens, Roy H.
collection PubMed
description Chronic prostatitis (CP) is a common inflammatory condition of the prostate that is estimated to effect 2%–10% of the world’s male population. It can manifest as perineal, suprapubic, or lower back pain and urinary symptoms occurring with either recurrent bacterial infection [chronic bacterial prostatitis (CBP)] or in the absence of evidence of bacterial infection [chronic pelvic pain syndrome (CPPS)]. Here, in the case of a 39 years-old CBP patient, we report the first successful use of a bacteriophage-derived muralytic enzyme (endolysin) to treat and resolve the disease. Bacteriological analysis of the patient’s prostatic secretion and semen samples revealed a chronic Enterococcus faecalis prostate infection, supporting a diagnosis of CBP. The patient’s E. faecalis strain was resistant to several antibiotics and developed resistance to others during the course of treatment. Previous treatment with multiple courses of antibiotics, bacteriophages, probiotics, and immunologic stimulation had failed to achieve long term eradication of the infection or lasting mitigation of the symptoms. A cloned endolysin gene, encoded by E. faecalis bacteriophage ϕEf11, was expressed, and the resulting gene product was purified to electrophoretic homogeneity. A seven-day course of treatment with the endolysin resulted in the elimination of the E. faecalis infection to below culturally detectable levels, and the abatement of symptoms to near normal levels. Furthermore, during the endolysin treatment, the patient experienced no untoward reactions. The present report demonstrates the effectiveness of an endolysin as a novel modality in managing a recalcitrant infection that could not be controlled by conventional antibiotic therapy.
format Online
Article
Text
id pubmed-10462781
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104627812023-08-30 Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis Stevens, Roy H. Zhang, Hongming Kajsik, Michal Płoski, Rafał Rydzanicz, Malgorzata Sabaka, Peter Šutovský, Stanislav Front Med (Lausanne) Medicine Chronic prostatitis (CP) is a common inflammatory condition of the prostate that is estimated to effect 2%–10% of the world’s male population. It can manifest as perineal, suprapubic, or lower back pain and urinary symptoms occurring with either recurrent bacterial infection [chronic bacterial prostatitis (CBP)] or in the absence of evidence of bacterial infection [chronic pelvic pain syndrome (CPPS)]. Here, in the case of a 39 years-old CBP patient, we report the first successful use of a bacteriophage-derived muralytic enzyme (endolysin) to treat and resolve the disease. Bacteriological analysis of the patient’s prostatic secretion and semen samples revealed a chronic Enterococcus faecalis prostate infection, supporting a diagnosis of CBP. The patient’s E. faecalis strain was resistant to several antibiotics and developed resistance to others during the course of treatment. Previous treatment with multiple courses of antibiotics, bacteriophages, probiotics, and immunologic stimulation had failed to achieve long term eradication of the infection or lasting mitigation of the symptoms. A cloned endolysin gene, encoded by E. faecalis bacteriophage ϕEf11, was expressed, and the resulting gene product was purified to electrophoretic homogeneity. A seven-day course of treatment with the endolysin resulted in the elimination of the E. faecalis infection to below culturally detectable levels, and the abatement of symptoms to near normal levels. Furthermore, during the endolysin treatment, the patient experienced no untoward reactions. The present report demonstrates the effectiveness of an endolysin as a novel modality in managing a recalcitrant infection that could not be controlled by conventional antibiotic therapy. Frontiers Media S.A. 2023-08-15 /pmc/articles/PMC10462781/ /pubmed/37649979 http://dx.doi.org/10.3389/fmed.2023.1238147 Text en Copyright © 2023 Stevens, Zhang, Kajsik, Płoski, Rydzanicz, Sabaka and Šutovský. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Stevens, Roy H.
Zhang, Hongming
Kajsik, Michal
Płoski, Rafał
Rydzanicz, Malgorzata
Sabaka, Peter
Šutovský, Stanislav
Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title_full Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title_fullStr Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title_full_unstemmed Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title_short Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
title_sort successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462781/
https://www.ncbi.nlm.nih.gov/pubmed/37649979
http://dx.doi.org/10.3389/fmed.2023.1238147
work_keys_str_mv AT stevensroyh successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT zhanghongming successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT kajsikmichal successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT płoskirafał successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT rydzaniczmalgorzata successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT sabakapeter successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis
AT sutovskystanislav successfuluseofaphageendolysinfortreatmentofchronicpelvicpainsyndromechronicbacterialprostatitis